文献速递头颈部肿瘤放疗

肌肉减少症对头颈癌放疗患者生存及晚期毒性的影响

Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy.
PubMed 文献 · Radiother Oncol · 2020-04-03

本研究纳入2007年1月至2016年6月接受根治性(放)化疗的750例头颈部鳞状细胞癌患者,利用放疗计划CT在C3水平评估骨骼肌以减少症。肌肉减少症与更差的总生存(HR 0.72,p=0.012)和无病生存(HR 0.67,p=0.001)独立相关,并与医生评定的口干和吞咽困难晚期毒性相关。

要点

  • 肌肉减少症是接受根治性(放)化疗头颈鳞癌患者生存更差的独立预后因素。
  • 肌肉减少症与治疗后6个月医生评定口干及6、12个月吞咽困难相关。
  • 口咽癌患者生存更多由p16状态而非肌肉减少症决定。

核心结论

  • 在接受根治性(放)化疗的头颈鳞癌患者中,肌肉减少症是生存结局更差的独立预后因素,并与医生评定的毒性相关。

研究设计与样本

  • 回顾性队列研究,纳入2007年1月至2016年6月接受根治性(放)化疗的750例头颈鳞状细胞癌患者。
  • 利用放疗计划CT在C3水平评估骨骼肌,以性别特异性最低四分位设定肌肉减少症截断值:男性SMI<42.4 cm²/m²、女性<30.6 cm²/m²。
  • 采用Kaplan-Meier法评估总生存和无病生存,多变量关联模型评估肌肉减少症对晚期毒性的影响。

主要发现

  • 肌肉减少症患者生存率显著更差,尤其是体能状态较低和局部晚期疾病患者。
  • 在口咽癌患者中,生存更多由p16状态而非肌肉减少症决定。
  • 多变量分析显示,肌肉减少症与更差的总生存(HR 0.72,p=0.012)和无病生存(HR 0.67,p=0.001)相关。
  • 肌肉减少症与治疗后6个月医生评定口干(OR 1.65,p=0.027)及6个月(OR 2.02,p=0.012)和12个月(OR 2.51,p=0.003)医生评定吞咽困难相关。

关键数值与推荐

  • 肌肉减少症截断值:男性SMI<42.4 cm²/m²,女性SMI<30.6 cm²/m²(对应性别特异性最低四分位)。
  • 总生存HR 0.72(p=0.012);无病生存HR 0.67(p=0.001)。
  • 6个月口干OR 1.65(p=0.027);6个月吞咽困难OR 2.02(p=0.012);12个月吞咽困难OR 2.51(p=0.003)。

临床怎么用

  • 对于接受根治性(放)化疗的头颈鳞癌患者,可基于放疗计划CT在C3水平评估肌肉减少症以辅助预后分层。
  • 对存在肌肉减少症的患者,应关注其生存预后及口干、吞咽困难等晚期毒性风险。
  • 在口咽癌患者中,p16状态对生存的预测价值可能优于肌肉减少症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Sarcopenia is emerging as an adverse prognostic factor for survival and complication risk in cancer patients. This study aims to determine the impact of sarcopenia on survival and late toxicity in a large cohort of head and neck squamous cell carcinoma (HNSCC) patients treated with definitive (chemo)radiotherapy ((C)RT). MATERIALS AND METHODS: HNSCC patients treated with definitive (C)RT from January 2007 to June 2016 were included. Sarcopenia was assessed from radiation planning computed tomography (CT) scans using skeletal muscles at level C3. The impact of sarcopenia on overall survival (OS) and disease-free survival (DFS) was evaluated using the Kaplan-Meier method. Multivariable association models were developed to assess the impact of sarcopenia on late toxicity. RESULTS: The study population was composed of 750 HNSCC patients. Cut-off values for sarcopenia were set at SMI < 42.4 cm2/m2 (men) and <30.6 cm2/m2 (women) corresponding lowest gender specific quartile. Sarcopenic patients had significantly poorer survival rates, especially those with lower performance status and locally advanced disease. In oropharyngeal cancer patients, survival was more determined by p16 status than by sarcopenia. In multivariable analysis, sarcopenia was associated with worse OS (HR 0.72, p = 0.012) and DFS (HR 0.67, p = 0.001). In multivariable association models, sarcopenia was associated with physician-rated xerostomia six months after treatment (OR 1.65, p = 0.027) and physician-rated dysphagia six and twelve months after treatment (OR 2.02, p = 0.012 and 2.51, p = 0.003, respectively). CONCLUSION: Sarcopenia in HNSCC patients receiving definitive (C)RT is an independent prognostic factor for worse survival outcomes and is associated with physician-rated toxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. van Rijn-Dekker MI, van den Bosch L, van den Hoek JGM, et al. Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy. Radiother Oncol. 2020. PMID: 32251949. doi:10.1016/j.radonc.2020.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。